Notably, we previously found no lower breast cancer–specific mortality among BRCA1/2 PV carriers vs noncarriers with HR-positive, HER2-negative disease in an analysis that included all women in the current study (15); thus, there is no evidence of mortality reduction from the more intensive regimens that BRCA1/2 PV carriers received for HR-positive, HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.